低疾病活动度特应性皮炎患者度普利尤单抗成功减量:BioDay登记处大型日常实践研究
这项前瞻性多中心研究纳入BioDay登记处595例接受度普利尤单抗治疗至少1.3年的成人特应性皮炎患者,其中401例在疾病持续控制后延长给药间隔。83.3%的患者减量成功,多数使用每3周或每4周方案;
要点
- 401例延长给药间隔的患者中83.3%减量成功,多数使用每3周或每4周方案。
- 减量后EASI最高均值3.5、瘙痒NRS最高均值3.2,较前小幅显著升高但保持低水平。
- 预测减量成功的所有纳入变量比值比均无统计学意义。
核心结论
- 在尝试减量的特应性皮炎患者中83.3%成功减量,同时维持疾病控制,多数使用每3周或每4周方案。
- 延长给药间隔对患者和社会经济角度均可能有益。
研究设计与样本
- 前瞻性多中心研究,纳入BioDay登记处接受度普利尤单抗治疗至少1.3年的成人特应性皮炎患者,共595例。
- 在标准剂量治疗至少1年且疾病持续控制(EASI≤7持续至少6个月)时考虑延长给药间隔。
- 采用逻辑回归分析减量成功的预后因素,并进行费用节省分析。
主要发现
- 595例患者中401例延长了度普利尤单抗给药间隔,减量开始时平均EASI 2.5(SD 2.3)、瘙痒NRS 2.4(SD 1.9)。
- 401例中83.3%减量成功,多数患者使用每3周或每4周方案。
- 减量后EASI最高均值3.5、瘙痒NRS最高均值3.2,较前显著小幅升高(P<0.001),但评分保持低水平。
- 预测减量成功的所有纳入变量比值比均无统计学意义。
关键数值与推荐
- 延长给药间隔条件:度普利尤单抗标准剂量至少1年且疾病持续控制(EASI≤7持续至少6个月)。
临床怎么用
- 作者认为,对于疾病持续控制的特应性皮炎患者,延长度普利尤单抗给药间隔对患者和社会经济角度均可能有益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited data are available regarding patient-centred dosing of dupilumab for atopic dermatitis (AD) in daily practice. OBJECTIVES: To evaluate our patient-centred dupilumab dosing regimen in daily practice, to assess prognostic factors for successful tapering and to estimate medication-related cost savings. METHODS: This prospective multicentre study included adult patients with AD, participating in the BioDay registry, treated with dupilumab for ≥ 1.3 years. Interval prolongation was considered in the case of dupilumab standard dose for ≥ 1 year and persistent controlled AD [Eczema Area and Severity Index (EASI) ≤ 7; ≥ 6 months]. Primary endpoints were the mean EASI and Numeric Rating Scale (NRS)-pruritus after the start of tapering. Prognostic factors for successful tapering were analysed with logistic regression and a cost-savings analysis was performed. RESULTS: A total of 595 patients were included, of whom 401 patients [mean EASI 2.5 (SD 2.3); NRS-pruritus of 2.4 (SD 1.9) at the start of tapering] prolonged their dupilumab interval. In 83.3% of these patients tapering was successful; most patients used dupilumab every 3 or 4 weeks (Q3W/Q4W). A significant small increase was observed for EASI (highest mean 3.5) and NRS-pruritus (highest mean 3.2) (P < 0.001); however, scores remained low. Predicting successful tapering showed nonsignificant odds ratios for all incorporated variables. The estimated cost savings was €3 977 033.98 for 401 patients between January 2019 and June 2022. CONCLUSIONS: This study showed successful tapering of dupilumab in 83.3% of patients with AD who attempted tapering, while maintaining controlled disease and with the majority using Q3W/Q4W. Interval prolongation can be beneficial both for the patient and from a socio-economic perspective.
引用
- Spekhorst LS, Boesjes CM, Loman L, et al. Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry. Br J Dermatol. 2023. PMID: 37177895. doi:10.1093/bjd/ljad159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。